TG Therapeutics, Inc.
0VGI.L
London Stock Exchange36.65
USD
-0.85
- -
TG Therapeutics, Inc.
0VGI.L
(London Stock Exchange)
Recent
price
36.65
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- TG Therapeutics, Inc. TG Therapeutics, Inc. (Ticker: 0VGI.L) is a fully integrated, commercial-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases, including malignancies and autoimmune disorders such as relapsing forms of multiple sclerosis (RMS). The company markets BRIUMVI (ublituximab-xiiy), an anti-CD20 monoclonal antibody indicated for the treatment of adult patients with RMS, encompassing clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease; its pipeline includes TG-1701, a novel, orally available, covalently bound Bruton's tyrosine kinase (BTK) inhibitor exhibiting selectivity for BTK; TG-1801, a bispecific CD47 and CD19 antibody targeting B-cell specific markers across malignancies; and azer-cel (azercabtagene zapreleucel), an allogeneic CD19 CAR T therapy, all in various stages of clinical development from Phase 1 to approved. TG Therapeutics, Inc. operates primarily in the United States, where it generates the majority of its revenue from BRIUMVI sales, with additional commercialization in other countries following approvals from regulatory agencies outside the U.S.; the company employs approximately 370 people and evaluates opportunities for in-licensing, partnerships, acquisitions, and investments in complementary products and technologies. Founded in 1993 and headquartered at 2 Gansevoort Street, 9th Floor, New York, NY 10014, United States, the company maintains strategic collaborations, including with Jiangsu Hengrui Medicine Co. and Checkpoint Therapeutics, Inc., to expand development and commercialization efforts; recent activities encompass a mixed shelf offering filing in August 2025, an ongoing equity buyback plan announced in August 2024, and a Phase 3 trial for a subcutaneous formulation of ublituximab, alongside upcoming third-quarter 2025 results disclosure and business update in November 2025.